Recursion Pharmaceuticals (RXRX) Research & Development (2020 - 2025)
Historic Research & Development for Recursion Pharmaceuticals (RXRX) over the last 6 years, with Q3 2025 value amounting to $121.1 million.
- Recursion Pharmaceuticals' Research & Development rose 6228.15% to $121.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $477.7 million, marking a year-over-year increase of 6726.76%. This contributed to the annual value of $314.4 million for FY2024, which is 3034.29% up from last year.
- According to the latest figures from Q3 2025, Recursion Pharmaceuticals' Research & Development is $121.1 million, which was up 6228.15% from $128.6 million recorded in Q2 2025.
- Over the past 5 years, Recursion Pharmaceuticals' Research & Development peaked at $129.6 million during Q1 2025, and registered a low of $24.1 million during Q1 2021.
- Its 5-year average for Research & Development is $64.5 million, with a median of $55.1 million in 2023.
- Per our database at Business Quant, Recursion Pharmaceuticals' Research & Development surged by 13331.72% in 2021 and then crashed by 892.9% in 2022.
- Quarter analysis of 5 years shows Recursion Pharmaceuticals' Research & Development stood at $48.3 million in 2021, then decreased by 8.93% to $44.0 million in 2022, then skyrocketed by 57.99% to $69.5 million in 2023, then soared by 41.52% to $98.3 million in 2024, then grew by 23.11% to $121.1 million in 2025.
- Its Research & Development stands at $121.1 million for Q3 2025, versus $128.6 million for Q2 2025 and $129.6 million for Q1 2025.